Additional funding brings Comphya’s series A to CHF 7.5 million
Comphya SA, a Lausanne-based company pioneering the first implantable neurostimulation therapy for erectile dysfunction (ED) unresponsive to medication, has closed an oversubscribed Series A financing round. Including the conversion of existing convertible loans, the round brings Comphya’s total equity raised to CHF 7.5 million (~USD 8.4 million).
Earlier this year, Comphya secured CHF 4.35 million in the first tranche of the Series A funding round to support clinical trials of its device, CaverSTIM, the first implantable neuromodulator designed to restore erectile function in patients non-responsive to oral drugs such as post- prostatectomy patients.
The ongoing first-in-human clinical trial in Australia where patients undergoing robotic-assisted prostatectomy were implanted with the CaverSTIM system is already showing strong safety and efficacy signals. Results were presented at the 2025 American Urological Association (AUA) Annual Meeting in Las Vegas showed that a large majority of patients maintained good erectile function postoperatively without the need for adjunctive therapies. No infections or adverse events were reported. These early outcomes underscore the potential of CaverSTIM to fill a major gap in post-prostatectomy care, an area with no effective therapeutic options today.
With additional funding from the second tranche of the series A round, Comphya plans to expand the Australia study by recruiting additional patients. The company will also use the funds to launch and execute a U.S. pilot study, with the first site activated at Johns Hopkins following FDA Investigational Device Exemption (IDE) approval announced in January 2025. Preparations for a pivotal U.S. clinical trial planned for 2026, including regulatory and operational groundwork will be facilitated by these fresh proceeds.
The U.S. pilot study, now underway at Johns Hopkins, builds on the strong early data from Australia. Combined insights from both regions will guide the design of a pivotal clinical trial in 2026, which Comphya plans to fund through a forthcoming Series B round.
The Series A round also coincides with recent leadership changes at Comphya, including the appointment of industry veteran Pim van Wesel as CEO in May 2025 to guide the company through its next stage of clinical growth and strategic execution.
“We are thrilled to have the continued confidence of our investors, which enables us to accelerate our mission to bring a transformative solution to men living with erectile dysfunction following treatment for prostate cancer,” said Pim van Wesel, CEO of Comphya. “With our U.S. pilot study underway and preparations beginning for a pivotal clinical trial, we’re entering an important new chapter in our development.”
(Press release/RAN)